https://www.gigamune.com/wp-content/uploads/2023/09/Screenshot-2023-12-04-at-9.26.54 AM.png
400
700
gigamune
https://www.gigamune.com/wp-content/uploads/2023/11/2023_GigaMune_Logo-transparent3.png
gigamune2023-09-30 09:41:002023-12-04 09:44:44GigaMune wins its seventh SBIR grantCell Therapy without the Cells
GigaMune is a San Francisco biotechnology company developing a pipeline of in vivo cell therapies for cancer and inherited blood disorders.
New treatments such as chimeric antigen receptor (CAR)-T cell therapy are efficacious but manufacturing bottlenecks decrease access for patients.
Our vision is to solve the manufacturing bottleneck by infusing virus-like gene delivery particles directly into patients.
David Johnson
Founder & CEO
Serial biotechnology entrepreneur with exits at Natera & GigaGen. Expert in applied molecular & computational genomics. PhD & postdoc at Stanford. MBA from UC Berkeley.
Matt Spindler
Founder & VP Research
Expert in cell engineering and virus like particle delivery. PhD from UCSF and postdoc at Stanford.
Everett Meyer
Founder & Clinical Adviser
Translational immunology professor & clinical practice in cell therapy at Stanford. Founder at GigaGen. MD/PhD at Stanford and Harvard.
Robert Edgar
Algorithms
World-renowned algorithm developer for bioinformatics (MUSCLE, USEARCH). Recently published methods for searching quadrillions of nucleotides in Nature.
Yoong Wearn Lim
Artificial Intelligence
Expert in artificial intelligence for drug discovery. PhD from UC Davis and postdoc at Genentech.
Eamon Byrne
Senior Scientist
Senior scientist in therapeutic protein screening & design. Postdoc at Stanford and PhD Oxford.
Software & wetware for discovery of viral envelopes, cell-tropic antibody fragments, and CARs
The best in vivo gene delivery particles and CAR-T therapies require very specific molecular targeting. But most drug developers rely on older technologies.
We are using powerful algorithms to search and analyze quadrillions of nucleotides to design in vivo gene delivery particles with exquisite targeting capabilities.
We are also using high-throughput genomics and artificial intelligence to identify CARs and cell-tropic antibodies for optimal pharmacology.
In vivo Cell Therapies for Cancer & Hereditary Blood Disorders
GigaMune is developing in vivo cell therapies for multiple myeloma, acute myeloblastic leukemia (AML), and inherited blood disorders such as sickle cell disease.
In addition to improving access, in vivo cell therapy does not require lymphodepletion, which is associated with medical risks and infertility.
In the News
https://www.gigamune.com/wp-content/uploads/2023/09/Screenshot-2023-12-04-at-9.26.54 AM.png
400
700
gigamune
https://www.gigamune.com/wp-content/uploads/2023/11/2023_GigaMune_Logo-transparent3.png
gigamune2023-09-30 09:41:002023-12-04 09:44:44GigaMune wins its seventh SBIR grant
https://www.gigamune.com/wp-content/uploads/2023/09/Screenshot-2023-12-04-at-9.26.32 AM.png
400
700
gigamune
https://www.gigamune.com/wp-content/uploads/2023/11/2023_GigaMune_Logo-transparent3.png
gigamune2023-08-30 09:23:002023-12-04 09:30:33Podium presentation by Dr. David Johnson at the 2023 CAR/TCR Summit
https://www.gigamune.com/wp-content/uploads/2023/09/Screenshot-2023-12-04-at-9.26.44 AM.png
400
700
gigamune
https://www.gigamune.com/wp-content/uploads/2023/11/2023_GigaMune_Logo-transparent3.png
gigamune2023-07-30 09:15:002023-12-04 09:30:55Podium presentation from Dr. David Johnson at the 2023 In Vivo Cell Engineering conferenceContact Us
GigaMune Inc.
953 Indiana St.
San Francisco, CA 94107